Our manufacturing process uses healthy, donor-derived PBMCs collected by apheresis, which eliminates a key supply bottleneck compared to autologous cell therapies. We expect manufacturing costs for iNKT cells to be significantly lower than the estimated manufacturing costs for autologous cell therapies.